Sfoglia per AUTORE
FAZI P
Collezione AO Cuneo
Items : 8
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. in Blood advances / Blood Adv. 2023 Aug 22;7(16):4448-4461. doi: 10.1182/bloodadvances.2022009596.
2023
AO Cuneo
AOU Città della Salute di Torino
Vitale A; Trappolini S; Guarini A; Latte G; Di Bartolomeo P; Cassibba V; Candoni A; Bonifacio M; De Fabritiis P; Bocchia M; Fracchiolla N; Mattei D; Martinelli G; Mauro E; Zappasodi P; Borlenghi E; Marbello L; Audisio E; Scattolin AM; De Propris MS; Elia L; Messina M; Paoloni F; Spinelli O; Santoro A; Della Starza I; Bassan R; Chiaretti S; Fazi P; et alii...
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.
2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara
Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R; Guarini A; Nanni M; Neri A; De Propris MS; De Novi LA; Visentin A; Vitale C; Albano F; Molinari MC; Pietrasanta D; Mattiello V; Liberati AM; Giordano A; Gottardi D; Patrizi VB; Galieni P; Musuraca G; Deodato M; Arcari A; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. in Blood advances / Blood Adv. 2022 Mar 22;6(6):1742-1753. doi: 10.1182/bloodadvances.2021004821.
2022
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
Baccarani M; Foà R; Fazi P; Vignetti M; Cavo M; Sartor C; Paolini S; Granier M; Wang M; Zhu Z; Abbenante MC; Galieni P; Fabbiano F; Trappolini S; Tosi P; Bonifacio M; Martelli MP; D'Ardia S; Cuneo A; Tedeschi A; Frison L; Bocchia M; Vitale A; Candoni A; Selleri C; Simonetti F; Lunghi M; de Fabritiis P; Lemoli RM; et alii...
Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors. in BMJ supportive & palliative care / BMJ Support Palliat Care. 2021 May 3:bmjspcare-2020-002312. doi: 10.1136/bmjspcare-2020-002312.
2021
AO Cuneo
Oswald LB; Venditti A; Cella D; Cottone F; Candoni A; Melillo L; Cairoli R; Storti G; Salutari P; Luppi M; Albano F; Martelli MP; Cuneo A; Tafuri A; Trisolini SM; Tieghi A; Fazi P; Vignetti M; Efficace F;
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. in Haematologica / Haematologica. 2021 Jun 1;106(6):1559-1568. doi: 10.3324/haematol.2020.247973.
2021
AOU Città della Salute di Torino
AO Cuneo
Vitale A; Cattaneo C; Mattei D; Fracchiolla N; Cerrano M; Cairoli R; Candoni A; Papayannidis C; De Fabritiis P; Di Raimondo F; Capria S; Apicella V; Spinelli O; Santoro A; Pierini V; Puzzolo MC; Lauretti A; Canichella M; La Starza R; Albertini Petroni G; Elia L; Ansuinelli M; Taherinasab A; Cavalli M; Cafforio L; Piciocchi A; Della Starza I; Messina M; Chiaretti S; et alii...
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.
2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara
Piciocchi A; Cuneo A; Foà R; Fazi P; Neri A; Guarini A; Rigolin GM; Nanni M; De Propris MS; Della Starza I; Raponi S; Del Giudice I; Murru R; Ruocco V; Ibatici A; Varettoni M; Laurenti L; Chiarenza A; Zinzani PL; Gentile M; Molinari A; Gozzetti A; Tani M; Musuraca G; Gottardi D; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. in Blood / Blood. 2019 Sep 19;134(12):935-945. doi: 10.1182/blood.2018886960. Epub 2019 Aug 8.
2019
AO Cuneo
Amadori S; Arcese W; Lo-Coco F; Voso MT; Lavorgna S; Ottone T; Irno-Consalvo M; Del Principe MI; Buccisano F; Vignetti M; Maurillo L; Fazi P; La Sala E; Alati C; Fracchiolla NS; Capelli D; Foà R; Tieghi A; Chierichini A; Fabbiano F; Tafuri A; Cuneo A; Albano F; Mazza P; Martelli MP; Luppi M; Martinelli G; Lanza F; Storti G; et alii...
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. in Blood advances / Blood Adv. 2019 Dec 23;3(24):4280-4290. doi: 10.1182/bloodadvances.2019000865.
2019
AOU Città della Salute di Torino
AO Cuneo
AOU Alessandria
AOU Novara
Soverini S; Vigneri P; Rosti G; Bonifacio M; Breccia M; Castagnetti F; Saglio G; Pane F; Russo D; Trabacchi E; Spadano R; Stagno F; Tiribelli M; Tomassetti S; Sancetta R; Sica S; Salvucci M; Rupoli S; Rege-Cambrin G; Rapezzi D; Pregno P; Miggiano MC; Montefusco E; Musolino C; Palmieri F; Malagola M; Melpignano A; Martino B; Marasca R; et alii...